# Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity

Study · id `cardio:ct-nct05098470` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05098470](<https://clinicaltrials.gov/study/NCT05098470>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05098470

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT05098470. Randomized; no masking; primary purpose other. Start 2022-03-07 (actual); primary completion 2025-07-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose other
- Phase: Phase 3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT05098470, source copy `cardio:ctgov-nct05098470-2025-07-30`, retrieved 2026-10-26)
- Started: 2022-03-07 (actual) (ClinicalTrials.gov record NCT05098470, source copy `cardio:ctgov-nct05098470-2025-07-30`, retrieved 2026-10-26)
- Primary completion: 2025-07-29 (actual) (ClinicalTrials.gov record NCT05098470, source copy `cardio:ctgov-nct05098470-2025-07-30`, retrieved 2026-10-26)
- Completion: 2026-07-29 (anticipated) (ClinicalTrials.gov record NCT05098470, source copy `cardio:ctgov-nct05098470-2025-07-30`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05098470, source copy `cardio:ctgov-nct05098470-2025-07-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05098470-2025-07-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
- Condition: Type 2 Diabetes
- Intervention (Drug): Metformin
- Intervention (Drug): Insulin Glargine
- Intervention (Drug): Dorzagliatin
- Lead sponsor: University of Alabama at Birmingham
- Lead sponsor class: OTHER
- Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: University of Alabama at Birmingham (`cardio:org-university-of-alabama-at-birmingham`)
- Registry lists this organization as a collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (`cardio:niddk`)

## Provenance

Content hash: 734720d88b3563b691de579e2154ac49f72700b7bbb3f0ad04e562bb0db791ee
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
